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Heart failure (HF) is thought to be a leading cause of car-dioembolic stroke.1 A meta-analysis of historical HF tri-
als (from the 1980s to the late 1990s) found that the annual 
stroke rate was between 1.3% and 2.4%.1,2 However, whether 
heart failure per se, rather than atrial fibrillation (AF) associ-
ated with HF, accounts for this high risk is uncertain because 
most analyses of stroke in HF did not disaggregate patients 
with and without AF. Furthermore, the total number of strokes 
in any individual study was usually small, in part, because of 
the relatively modest size and short duration of many trials in 
HF. As a consequence, the risk of stroke in patients with HF 
but without AF is poorly defined, particularly in a contempo-
rary population.
Editorial see p 1465 
Clinical Perspective on p 1494
Background—Our aim was to describe the incidence and predictors of stroke in patients who have heart failure without 
atrial fibrillation (AF).
Methods and Results—We pooled 2 contemporary heart failure trials, the Controlled Rosuvastatin in Multinational Trial 
Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell’Insufficienza cardiaca-Heart 
Failure trial (GISSI-HF). Of the 9585 total patients, 6054 did not have AF. Stroke occurred in 165 patients (4.7%) with 
AF and in 206 patients (3.4%) without AF (rates 16.8/1000 patient-years and 11.1/1000 patient-years, respectively). 
Using Cox proportional-hazards models, we identified the following independent predictors of stroke in patients without 
AF (ranked by χ2 value): age (hazard ratio, 1.34; 95% confidence interval, 1.18–1.63 per 10 years), New York Heart 
Association class (1.60, 1.21–2.12 class III/IV versus II), diabetes mellitus treated with insulin (1.87, 1.22–2.88), body 
mass index (0.74, 0.60–0.91 per 5 kg/m2 up to 30), and previous stroke (1.81, 1.19–2.74). N-terminal pro B-type natriuretic 
peptide (available in 2632 patients) was also an independent predictor of stroke (hazard ratio, 1.31; 1.11–1.57 per log 
unit) when added to this model. With the use of a risk score formulated from these predictors, we found that patients in 
the upper third of risk had a rate of stroke that approximated the risk in patients with AF.
Conclusions—A small number of demographic and clinical variables identified a subset of patients who have heart failure without 
AF at a high risk of stroke.  (Circulation. 2015;131:1486-1494. DOI: 10.1161/CIRCULATIONAHA.114.013760.)
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HF, particularly HF with reduced ejection fraction (HF-REF), 
without AF may predispose to stroke through fulfillment of 
the Virchow triad for thrombogenesis.2,3 First, patients with 
HF may have stasis of blood flow (blood flow abnormalities) 
related to left ventricular systolic dysfunction and dyskinesis.4,5 
Second, patients with HF also have endocardial and endothe-
lial dysfunction (vessel wall abnormalities).4,5 Both of these 
problems may also lead to cerebral hypoperfusion and cerebral 
blood flow dysregulation, further increasing the risk of stroke. 
Third, patients with HF have a hypercoagulable state (abnor-
mal blood constituents).4,5 Importantly, with the availability of 
highly effective oral anticoagulant treatment, strokes potentially 
related to these factors may be preventable. In the Warfarin/
Aspirin Study in Heart Failure (WASH), there was no signifi-
cant difference among the groups of patients receiving warfa-
rin, aspirin, and placebo, in the composite end point of death, 
stroke, or myocardial infarction, although this was a small trial.6 
The larger Warfarin and Antiplatelet Therapy in Chronic Heart 
Failure trial (WATCH), which was terminated prematurely 
owing to slow recruitment, suggested that there was a reduc-
tion in the rate of ischemic stroke with warfarin in comparison 
with aspirin.7 The Warfarin versus Aspirin in Reduced Cardiac 
Ejection Fraction trial (WARCEF), which was the most recent 
and by far the largest study, showed the potential thrombopro-
phylaxis benefit of warfarin in WARCEF, although this was 
offset by an increased risk of major hemorrhage.8 This finding 
highlights the need to better understand the risk and predictors 
of stroke in a contemporary HF population. Identification of 
those at highest risk of stroke coupled with the availability of 
newer oral anticoagulants that cause less bleeding might allow 
individualized and safer stroke treatment strategies in patients 
with HF without AF. In other words, it may be possible, with 
effective risk stratification and safer anticoagulants, to identify 
a subset of HF patients without AF in whom the potential reduc-
tion in stroke outweighs the risk of major bleeding.
We therefore combined and analyzed patient-level data from 
2 large and contemporary HF trials, the Controlled Rosuvastatin 
in Multinational Trial Heart Failure (CORONA, ClinicalTrials.
gov NCT00336336)9 and the Gruppo Italiano per lo Studio 
della Sopravvivenza nell’Insufficienza cardiac-Heart Failure 
trial (GISSI-HF, ClinicalTrials.gov NCT00206310),10 to pro-
vide a comprehensive description of the current incidence of 
and risk factors for stroke in patients with HF. We compared 
the rate of stroke in patients without AF, according to different 
risk categories, with the rate in those with AF.
Methods
Study Populations
To have a sufficiently large number of patients with HF and without 
AF, we pooled GISSI-HF and CORONA because both were recently 
conducted and neither showed an effect of study drug on the risk of 
the primary outcome or on stroke. Each was a randomized, double-
blind, placebo-controlled, multicenter trial that enrolled 4574 and 
5011 patients, respectively, with chronic HF.9,10 Together, these trials 
included a broad spectrum of patients with HF. CORONA enrolled 
patients aged ≥60 years with New York Heart Association (NYHA) 
functional class II to IV and HF-REF of ischemic etiology. Patients 
with NYHA class III to IV symptoms were eligible if their left ven-
tricular ejection fraction (LVEF) was ≤40% (and class II patients if 
their LVEF was ≤35%). The primary outcome was the composite 
of cardiovascular death, myocardial infarction, or stroke. GISSI-HF 
enrolled patients with stable chronic HF (NYHA II–IV), irrespective 
of age, etiology, and LVEF, that is, both patients with HF-REF and 
HF with preserved ejection fraction (HF-PEF) were included. Patients 
with HF-PEF (LVEF >40%) had to have experienced a HF hospital-
ization in the year before enrolment. The coprimary outcomes were 
death from any cause and the composite of death from any cause or 
cardiovascular hospitalization. In GISSI-HF patients were randomly 
assigned to placebo or n-3 polyunsaturated fatty acids; 4574 were also 
randomly assigned to placebo or rosuvastatin 10 mg daily in a facto-
rial design. In CORONA, patients were randomly assigned to 10 mg 
of rosuvastatin or matching placebo, once daily. The first patient was 
randomly assigned on August 6, 2002 in GISSI-HF and September 
15, 2003 in CORONA. The median follow-up in GISSI-HF was 3·9 
years, and in CORONA the median follow-up was 2.7 years. Both 
trials were approved by the local ethics committees and conformed to 
the principles outlined in the Declaration of Helsinki. In GISSI-HF, 
n-3 polyunsaturated fatty acid treatment led to a small but statistically 
significant reduction in both coprimary end points, but it had no effect 
on the risk of stroke. Rosuvastatin did not reduce the primary outcome 
(or the risk of stroke) in either trial. The number of deaths from any 
cause in GISSI-HF and CORONA was 1301 and 1487, respectively.
Stroke End Point
Incident strokes were centrally adjudicated by an independent end 
point committee in each trial, and stroke was part of the primary or 
secondary composite cardiovascular outcomes in both trials.9,10
Incident AF
AF was prospectively collected in GISSI-HF. AF occurrence during 
the trial was defined as: the presence of AF on any of the ECGs per-
formed at each follow-up visit, AF as a cause of worsening HF or 
hospital admission, and AF as an event occurring during a hospital 
admission. The occurrence of AF was not recorded prospectively 
in CORONA. However, we retrospectively analyzed adverse event 
reports for the occurrence of AF.
N-Terminal pro B-Type Natriuretic Peptide
In both studies, N-terminal pro B-type natriuretic peptide 
(NT-proBNP) was measured in a subset of patients at a central 
laboratory with the use of a commercially available assay (Roche 
Diagnostics, Basel, Switzerland).
Statistical Methods
Patients with AF were defined as those with either AF confirmed 
on their baseline ECG or a history of AF. The remaining patients 
were defined as those without AF. Descriptive statistics were used to 
describe the pooled patient population from both trials and to com-
pare these 2 subgroups, using means (standard deviation) or medians 
(interquartile range [IQR]) for continuous variables and count (per-
centage) for categorical variables.
The incidence rates of stroke (per 1000 patient-years) were calcu-
lated during the trial follow-up period and were compared between 
the aforementioned patient subgroups. Cumulative incidence func-
tions of stroke occurrences were estimated accounting for competing 
risk of death.11,12 To satisfy the assumption of the independence of 
stroke events, recurrent stroke events in a patient after randomization 
were not included in the analysis. Uni- and multivariable predictors 
of risk for stroke were assessed by using the Cox proportional hazards 
regression analysis. Continuous variables (eg, body mass index and 
ejection fraction) were evaluated by visual inspection of restricted 
cubic splines to identify potential nonlinear effects. For the multivari-
able analysis, we used previously established predictors of ischemic 
stroke13–18 and added variables from our unadjusted univariable analy-
ses that were significant at P<0.05. The multivariable analysis was 
performed in 2 steps, only including patients without AF.
In step 1, a best clinical model was created from the pooled data 
set of patients without AF by using standard modeling techniques.15 
Eight variables that were found to be statistically significant from the 
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unadjusted univariable analyses were included age, body mass index, 
NYHA class, and history of coronary heart disease, peripheral artery 
disease, stroke, diabetes mellitus treated with insulin, and creatinine.
In step 2, (log
e
) NT-proBNP was added to the independent vari-
ables identified in the step 1 model, although this test was only avail-
able in a subset of patients.
There were no data missing for the baseline variables used in the 
multivariable models. We calculated the hazard ratio and corresponding 
95% confidence intervals (95% CIs) to express the hazard rate of stroke. 
The statistical contribution of each variable to the predicted stroke was 
assessed by using the χ2 statistic. The coefficients from statistically sig-
nificant variables in the multivariable model were used to calculate an 
individual patient’s risk score for stroke. Cumulative incidence func-
tion for stroke was estimated by using the competing risk technique11,12 
according to tertiles of risk score. Where appropriate, the corresponding 
Kaplan–Meier curves for stroke occurrences were also plotted.
Model calibration and the ability to separate populations of patients 
into risk groups were assessed by observing predicted versus observed 
outcomes in tertiles, and by using the Hosmer-Lemeshow goodness-
of-fit test. The models’ discrimination abilities were evaluated by the 
C statistics. All analyses were undertaken by using SAS version 9.2 
(SAS Institute, Inc, Cary, NC). The authors had full access to the data 
sets and vouch for data integrity. All authors have read and agreed to 
the manuscript as written.
Results
A total of 9585 patients were included in this analysis, of 
which 3531 had AF on their baseline ECG, or a history of AF, 
and 6054 patients had no AF.
NT-proBNP measurements were available in 4381 patients 
(45.7%) overall (1749 patients [49.5%] with AF and 2632 
patients [43.5%] without AF).
Baseline Characteristics
The baseline characteristics of patients with and without AF 
are shown in Table I in the online-only Data Supplement. The 
Table 1. Baseline Characteristics of Patients Without AF 
According to Stroke Outcome
Patients 
Without AF
(N=6054)
Nonstroke
(n=5848)
Stroke
(n=206)
Demographics, n (%)
  Age, y 69±10 69±10 72±9
   <60 777 (13) 760 (13) 17 (8)
   60–<65 906 (15) 880 (15) 26 (13)
   65–<75 2539 (42) 2466 (42) 73 (35)
   ≥75 1832 (30) 1742 (30) 90 (44)
  Female sex 1431 (24) 1388 (24) 43 (21)
  NYHA class
   II 3236 (53) 3148 (54) 88 (43)
   III 2724 (45) 2612 (45) 112 (54)
   IV 94 (2) 88 (2) 6 (3)
  Duration of heart failure, y
   <2 2697 (45) 2611 (45) 86 (42)
   2–5 2058 (34) 1987 (34) 71 (34)
   >5 1295 (21) 1246 (21) 49 (24)
  LV ejection fraction, n % 32±7 32±7 31±8
   >40% 216 (4) 207 (4) 9 (5)
   ≤40 and >30% 3138 (52) 3040 (52) 98 (48)
   ≤30% 2700 (45) 2601 (44) 99 (48)
Baseline vital signs
  BMI, kg/m2 27±4 27±4 26±4
  BP, mm Hg
   Systolic 128±17 128±17 129±17
   Diastolic 77±9 77±10 77±9
   Pulse pressure 52±13 52±13 51±14
  Heart rate, beats/min 71±12 71±12 72±11
Laboratory measurements
  Total cholesterol, mmol/L 5.3±1.1 5.3±1.1 5.2±1.0
  Serum creatinine, μmol/L 107±30 107±30 111±30
  eGFR, mL/min per 1.73 m2 65±20 65±20 62±19
  eGFR <60, n (%) 2581 (43) 2476 (42) 105 (51)
  NT-proBNP, pmol/L, median (IQR) 121 (9–233) 119 (8–230) 169 (42–297)
Medical history, n (%)
  Myocardial infarction 3003 (50) 2892 (50) 111(54)
  Angina pectoris 2521 (42) 2421 (41) 100 (49)
  CABG or PCI 1472 (24) 1427 (24) 45 (22)
  Hypertension 3450 (57) 3326 (57) 124 (60)
  Diabetes mellitus 1714 (28) 1648 (28) 66 (32)
  Stroke 424 (7) 398 (7) 26 (13)
  Pacemaker 595 (10) 573 (10) 22 (11)
  ICD or CRT 297 (5) 289 (5) 8 (4)
  Peripheral artery disease 578 (10) 550 (9) 28 (14)
  Current smoker 864 (14) 833 (14) 31 (15)
Medication, n (%)
  Diuretic (not aldosterone  
antagonist)
5242 (87) 5061 (87) 181 (88)
  ACE inhibitor or ARB 5646 (93) 5458 (93) 188 (91)
  Aldosterone antagonist 2245 (37) 2165 (27) 80 (39)
  β-Blocker 4285 (71) 4142 (71) 143 (69)
  Digitalis glycoside 1595 (26) 1536 (26) 59 (28)
  Long-acting nitrate 2058 (34) 1971 (34) 87 (42)
  Antiarrhythmic drug 736 (12) 720 (12) 16 (8)
  Antiplatelet therapy 4094 (68) 3947 (67) 147 (71)
  Anticoagulant therapy 963 (16) 930 (16) 33 (16)
  Antiplatelet or anticoagulant 
therapy
4953 (82) 4776 (82) 177 (86)
  Antidiabetic drugs
   Insulin 467 (8) 443 (8) 24 (12)
   Oral hypoglycemic 997 (16) 970 (17) 27 (13)
All continuous values are given in mean±standard deviation unless stated 
otherwise. ACE indicates angiotensin-converting enzyme; AF, atrial fibrillation; 
ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; 
CABG, coronary artery bypass graft; CRT, cardiac resynchronization therapy; eGFR, 
estimated glomerular filtration rate; ICD, implantable cardioverter defibrillator; IQR, 
interquartile range; LV, left ventricular; n (%), number of observations (percentage of 
observations within the group); NT-ProBNP, N-terminal pro B-type natriuretic peptide; 
NYHA, New York Heart Association; and PCI, percutaneous coronary intervention.
Table 1. Continued
Patients 
Without AF
(N=6054)
Nonstroke
(n=5848)
Stroke
(n=206)
(Continued)
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characteristics of patients without AF, according to subse-
quent stroke, are shown in Table 1.
Patients With and Without AF
Patients without AF were slightly younger, had a slightly 
lower LVEF, and had better NYHA functional class. 
Patients without AF also had a higher mean estimated glo-
merular filtration rate and lower median NT-proBNP level 
than patients with AF. There were also several differences 
in medical history/comorbidity, notably in history of myo-
cardial infarction and hypertension with the former more 
common and the latter less frequent in patients without AF 
(in comparison with those with AF). There were also nota-
ble differences in medical therapy, particularly in the use 
of antiplatelet therapy (68% of patients without AF versus 
36% in those with AF) and anticoagulant treatment (16% 
versus 62%, respectively).
Patients Without AF With and Without Stroke During 
Follow-Up
Patients without AF who experienced stroke were older than 
those who did not, had worse NYHA class, and higher cre-
atinine levels. Patients with stroke were more likely to have a 
history of prior stroke, myocardial infarction, peripheral arte-
rial disease, hypertension, and diabetes mellitus.
The baseline characteristics of the 4381 patients with a 
NT-proBNP measurement at baseline are shown in Tables II 
and III in the online-only Data Supplement. These did not dif-
fer significantly from the overall population.
Number at risk of stroke
Without AF 6054 5983 5921 5872
With AF 3531 3472 3432 3388
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Figure 1. Cumulative incidence function of stroke by AF status 
at baseline (with death as competing risk). AF indicates atrial 
fibrillation.
Figure 2. The relationship between 
baseline variables and risk of stroke 
in patients without atrial fibrillation. 
Variables are described in quintiles. AF 
indicates atrial fibrillation; BMI, body 
mass index; BP, blood pressure; LV, left 
ventricle; and NT-proBNP, N-terminal pro 
B-type natriuretic peptide.
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Rates of Stroke
Patients With AF
The median follow-up time in patients with AF was 2.97 
(IQR, 2.22–3.49) years and 165 of these 3531 patients expe-
rienced a stroke (16.8/1000 patient-years). The 1-, 2-, and 
3-year cumulative incidence function (CIF) rates of stroke 
were 1.7% (95% CI, 1.3–2.1), 2.8% (95% CI, 2.3–3.4), and 
4.2% (95% CI, 3.6–4.9), respectively (Figure 1). The rate 
in patients treated with an anticoagulant was 14.0 per 1000 
patient-years, and, in those not treated, it was 21.7 per 1000 
patient-years. In patients treated with an anticoagulant, the 1-, 
2-, and 3-year CIF rates of stroke were 1.3% (95% CI, 0.9–
1.8), 2.3% (95% CI, 1.7–3.0), and 3.6% (95% CI, 2.9–4.5), 
respectively (Figure I in the online-only Data Supplement); 
the corresponding CIF rates for patients not treated with an 
anticoagulant were 2.3% (95% CI, 1.6–3.2), 3.7% (95% CI, 
2.7–4.8), and 5.2% (95% CI, 4.1–6.4), respectively (Figure I 
in the online-only Data Supplement).
The median follow-up time in the 1749 patients with AF 
and a NT-proBNP measurement at baseline was 2.61 (IQR, 
2.17–3.04) years; 86 of these patients experienced a stroke 
(rate 20.3/1000 patient-years).
Patients Without AF
The median follow-up time in patients without AF was 3.18 
(IQR, 2.45–3.98) years, and 206 of these 6054 patients expe-
rienced a stroke (11.1/1000 patient-years). The 1-, 2-, and 
3-year CIF rates of stroke were 1.2% (95% CI, 0.9–1.5), 2.2% 
(95% CI, 1.9–2.6), and 3.1% (95% CI, 2.7–3.6), respectively 
(Figure 1). The median follow-up time in the 2632 patients 
without AF but with a NT-proBNP measurement at baseline 
was 2.78 (IQR, 2.30–3.12) years; 94 of these patients experi-
enced a stroke (rate 13.5/1000 patient-years).
Incident AF and Risk of Stroke
In GISSI-HF, 3138 patients did not have AF at baseline. Of 
these, 85 patients (2.7%) experienced a stroke. Of these 85 
patients, 13 (15.3%) developed new AF before the occurrence 
of their stroke; the number of patients with a stroke without 
preceding AF was 72 (84.7%). Nineteen patients (22.4%) 
with an incident stroke had new AF found before or after their 
stroke.
In CORONA, 2916 patients did not have AF at baseline. Of 
these, 121 patients (4.1%) experienced a stroke. Of these 121 
patients, 9 (7.4%) developed new AF before the occurrence of 
their stroke; the number of patients with a stroke without pre-
ceding AF was 112 (92.6%). Fourteen patients (11.6%) with 
an incident stroke had new AF reported before or after their 
stroke.
Predictors of Stroke in Patients Without AF: Model 
Without NT-proBNP
Figure 2 and Table IV in the online-only Data Supplement 
(unadjusted analysis) show the relationship between baseline 
variables and the risk of stroke. Table 2 shows the indepen-
dent predictors of stroke (without inclusion of NT-proBNP). 
The 5 variables that were significant in the multivariable 
Figure 3. Distribution of the risk score for stroke–best clinical 
model (ie, model without NT-proBNP). NT-proBNP indicates 
N-terminal pro B-type natriuretic peptide.
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Figure 4. Cumulative incidence function plot for stroke by tertiles 
of their risk scores in patients without AF–best clinical model (ie, 
model without NT-proBNP [with death as competing risk]). AF 
indicates atrial fibrillation; and NT-proBNP, N-terminal pro B-type 
natriuretic peptide.
Table 2. Best Clinical Model for Stroke Based on Forward Stepwise Cox Proportional Hazard Regression
Variables Hazard Ratio Lower 95% CI Upper 95% CI χ2 Value Coefficients Standard Error P Value
Age (per 10 y increase) 1.34 1.18 1.63 16.2 0.331 0.082 <0.001
NYHA class (NYHA III and IV) 1.60 1.21 2.12 10.8 0.472 0.143 0.001
Diabetes mellitus treated with insulin 1.87 1.22 2.88 8.1 0.626 0.220 0.004
BMI (per 5 kg/m2 increase up to 30) 0.74 0.60 0.91 7.9 –0.301 0.107 0.005
Previous stroke 1.81 1.19 2.74 7.8 0.591 0.212 0.005
There were no missing data for the variables included in the model above. Variables arranged by descending χ2 value. See the online-only Data Supplement for an 
explanation of how to use coefficients of the variables to calculate individual patient’s risk score of stroke. BMI indicates body mass index; CI, confidence interval; and 
NYHA, New York Heart Association.
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model did not include blood pressure or ejection fraction. 
The model in Table 2 can be used to calculate an individ-
ual’s risk of stroke as described in the online-only Data 
Supplement Appendix.
Figure 3 shows the distribution of the risk score for stroke. 
Figure 4 shows the CIF plot for stroke with patients classified 
into 3 equal-sized groups according to risk score. The num-
ber of strokes in tertiles 1, 2, and 3 were 36, 66, and 104, 
respectively. The 1-, 2-, and 3-year CIF rates of stroke in the 
2 higher risk tertiles were as follows: tertile 2, 1.1% (95% 
CI, 0.7–1.7), 2.0% (95% CI, 1.4–2.7), and 2.9% (95% CI, 
2.2–3.7), respectively; and tertile 3, 1.8% (95% CI, 1.3–2.4), 
3.5% (95% CI, 2.8–4.4), and 5.0% (95% CI, 4.1–6.1), respec-
tively. The 1-, 2-, and 3-year Kaplan–Meier rates of stroke in 
the 2 higher-risk tertiles were as follows: tertile 2, 1.2% (95% 
CI, 0.8–1.8), 2.1% (95% CI, 1.6–2.9), and 3.2% (95% CI, 
2.4–4.1), respectively, and tertile 3, 1.9% (95% CI, 1.4–2.6), 
4.1% (95% CI, 3.2–5.1), and 5.9% (95% CI, 4.8–7.2), respec-
tively (Figure 5). Patients in risk tertile 3 had an overall stroke 
rate of 19.8 per 1000 patient-years.
Figure 6 shows the model’s goodness of fit by comparing 
observed and expected probabilities of stroke at 3 years with 
the patients divided into tertiles. The calibration was also 
assessed by using the Hosmer-Lemeshow test, which was 
P=0.122. Model discrimination was evaluated by using the C 
index, which was 0.75 (95% CI, 0.62–0.86).
Predictors of Stroke in Patients Without AF: Model 
Including NT-proBNP
When NT-proBNP was added to the 5 predictive variables 
described above, only 2 of the previous variables, along with 
log NT-proBNP, remained independent predictors: diabetes 
mellitus treated with insulin and history of stroke (Table 3). 
The model in Table 3 can be used to calculate an individual’s 
risk of stroke as described in the online-only Data Supplement 
Appendix.
Figure II in the online-only Data Supplement shows the dis-
tribution of the risk score for stroke. Figure 7 shows CIF plots 
for stroke with patients classified into 3 equal-sized groups 
according to risk score. The number of strokes in tertiles 1, 
2, and 3 were 16, 34, and 44, respectively. The 1-, 2-, and 
3-year CIF rates of stroke in the 2 higher-risk tertiles were 
tertile 2, 1.4% (95% CI, 0.7–2.3), 2.5% (95% CI, 1.6–3.7), 
and 3.8% (95% CI, 2.6–5.4), respectively; and tertile 3, 1.9% 
(95% CI, 1.2–3.0), 3.3% (95% CI, 2.3–4.6), and 5.9% (95% 
CI, 4.2–7.9), respectively. Patients in risk tertile 3 had an over-
all stroke rate of 22.9 per 1000 patient-years.
Figure III in the online-only Data Supplement shows the 
model’s goodness of fit, as described above. Calibration was 
good (P=0.644 for the Hosmer-Lemeshow test).
The C index for the model including NT-proBNP was 
0.80 (95% CI, 0.61–0.94), which was not significantly dif-
ferent from the C index for the model without NT-proBNP 
(P=0.185).
Validation of Risk Model
We tested the predictive model in the Candesartan in Heart 
Failure: Reduction in Mortality and morbidity (CHARM) 
HF-REF trials.19,20 These trials included 1227 patients with 
and 3349 patients without AF. The median follow-up was 40 
months. There were 59 strokes in the patients with AF and 107 
strokes in those without AF, giving stroke rates in patients with 
and without AF 18.3 and 11.4 per 1000 patient-years, respec-
tively. We tested the model without NT-proBNP because natri-
uretic peptides were not measured in CHARM.
Using the same analytic approach (Table V in the online-
only Data Supplement, Figures IV and V in the online-only 
Data Supplement), the 1-, 2-, and 3-year CIF rates of stroke in 
the 2 higher-risk tertiles were as follows: tertile 2, 1.4% (95% 
CI, 0.8–2.2), 1.8% (95% CI, 1.1–2.7), and 2.7% (95% CI, 
1.9–3.8), respectively; and tertile 3, 1.5% (95% CI, 0.9–2.4), 
3.1% (95% CI, 2.2–4.2), and 4.3% (95% CI, 3.2–5.6), respec-
tively. Patients in risk tertile 3 of the validation model derived 
from CHARM HF-REF trials had an overall stroke rate of 
17.9 per 1000 patient-years. The C index for the model was 
0.71 (95% CI, 0.52–0.87).
The corresponding Kaplan–Meier curves for the CIFs of 
stroke described above are available in Figures VI through 
VIII in the online-only Data Supplement).
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Figure 5. Kaplan–Meier plot for stroke by tertiles of their risk 
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Discussion
We confirmed that HF patients with AF are at high risk of 
stroke, with an average incidence rate of 1.6% per year, despite 
anticoagulant treatment in 62% of the patients. Patients with-
out AF, overall, had a lower, but still substantial, risk of 1.2% 
per year. However, a small number of demographic and clini-
cal variables identified a subset of these patients without AF 
who were at greater risk. Specifically, patients in the upper 
tertile of the risk score had a rate of stroke that approximated 
the risk of patients with AF and not treated with an anticoagu-
lant in the 2 trials analyzed (2.0% per year versus 2.2% per 
year, respectively).
The risk of stroke in our patients without AF was similar 
to the risk of stroke in WARCEF patients treated with aspirin, 
which was ≈1.4% per year,8 especially taking account of the 
fact that 16% of our patients were treated with an oral antico-
agulant (and 82% were treated with an anticoagulant or anti-
platelet agent) at baseline. A lower thromboembolism rate of 
1.0% per year was reported by the SCD-HeFT investigators in 
patients who have systolic HF without AF (56 of the 71 events 
were a stroke).13 This lower rate of events in SCD-HeFT 
might be explained by the higher use of antithrombotic ther-
apy at baseline (warfarin in 28% and aspirin in 59%) in that 
study. In our patients with AF, the risk of stroke or systemic 
embolism was less than in AF patients with HF treated with 
warfarin in RELY-AF21 (1.9% per year) and ROCKET-AF22 
(2.1%), and patients with left ventricular systolic dysfunction 
in ARISTOTLE23 (1.8%), as well. This is likely explained by 
the requirement for patients in these trials to have additional 
risk factors for stroke. These previous reports suggest that our 
findings are at least generalizable to other patients with HF in 
clinical trials.
Interestingly, LVEF was not predictive of stroke in our 
study, despite some, but not all, previous studies suggesting 
otherwise.24,25 These previous studies did not differentiate 
between patients with and without AF, however. Furthermore, 
in our study, neither systolic blood pressure nor history of 
hypertension were predictive of stroke. Although this is at 
variance with studies in other patient populations, it is consis-
tent with the reverse epidemiology of HF and the recognized 
association between higher blood pressure and better out-
comes in this condition.26–28 A similar reverse epidemiologi-
cal relationship was noted between both body mass index and 
low-density lipoprotein cholesterol and stroke.27,28
NT-proBNP was measured in approximately half of patients. 
NT-proBNP was an independent predictor of stroke when 
added to the variables described above. Indeed, the resultant 
model contained only 2 other predictive variables. However, 
the addition of NT-proBNP did not improve the model C sta-
tistic significantly. Although the value of NT-proBNP is a pre-
dictor of adverse outcomes in HF, to our knowledge, this is the 
first demonstration that NT-proBNP is a predictor of stroke in 
patients without AF. This finding adds to recent observations 
that NT-proBNP is an independent predictor of stroke risk in 
patients with AF.29–31
A particular strength of this study is the validation of our 
predictive model in another data set. Consequently, our find-
ings have clear clinical implications. With a small number of 
routinely collected clinical variables, it is possible to identify 
patients with HF but without AF who are at sufficiently high risk 
of stroke to potentially justify anticoagulation. Clearly, there is 
as yet no trial evidence to justify such treatment, but our findings 
suggest a means of identifying patients for such a trial. It may 
even be that measurement of plasma NT-proBNP concentration 
on its own may be sufficient to risk stratify patients with respect 
to stroke, and this possibility should be investigated further.
Limitations
The number of strokes overall was modest but greater than 
in any previous study. Each of the 2 trials included had spe-
cific selection criteria and, hence, our findings may not be 
generalizable to all patients with HF, particularly patients 
with HF-PEF who were largely excluded from this analysis. 
Although our data suggest that only the minority of strokes are 
related to incident AF, detection of new-onset AF was subopti-
mal. New-onset AF was collected systematically in GISSI-HF 
but not in CORONA. However, even in GISSI-HF, paroxysms 
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Figure 7. Cumulative incidence function plot for stroke by tertiles 
of their risk scores in patients without AF – model including 
NT-proBNP (with death as competing risk). AF indicates atrial 
fibrillation; and NT-proBNP, N-terminal pro B-type natriuretic 
peptide.
Table 3. Final Model for Stroke Based on Forward Stepwise Cox Proportional Hazard Regression, Adding NT-proBNP to 
Independent Predictors Identified in Table 2 (n=2632)
Variables Hazard Ratio Lower 95% CI Upper 95% CI χ2 Value Coefficients Standard Error P Value
Log NT-ProBNP 1.32 1.11 1.57 10.4 0.280 0.087 0.001
Diabetes mellitus treated with insulin 2.09 1.19 3.70 6.5 0.739 0.290 0.011
Previous stroke 1.92 1.10 3.35 5.3 0.653 0.283 0.021
There were no missing data for the variables included in the model above. The model as applied to subset of patients with NT-proBNP measurement at baseline only. 
Variables are arranged by descending χ2 value. See the online-only Data Supplement for an explanation of how to use coefficients of the variables to calculate individual 
patient’s risk score of stroke. CI indicates confidence interval; and NT-proBNP, N-terminal pro B-type natriuretic peptide.
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of AF may not have been detected because ambulatory moni-
toring was not performed. It is well known that subclinical 
AF is common in HF and it is possible (or even likely) that 
many more strokes might be related to unrecognized/unde-
tected AF. However, waiting for the development of clinically 
recognized AF before using anticoagulant therapy may not 
be the optimum preventive strategy. An alternative approach 
might be to screen for subclinical AF, but how to best do this 
is uncertain. Should this be done with ambulatory monitor-
ing or an implanted device? If the former, how often would 
this screening have to be repeated? How much would either 
strategy cost? Moreover, as described above, there are other 
reasons why patients with HF are at risk of thromboembolic 
and other types of ischemic stroke. We believe that our data 
support the possibility of a broader preventive role for anti-
coagulant therapy in HF patients in sinus rhythm, especially 
as new agents with a lower risk of bleeding are available. Of 
course, this hypothesis needs to be tested prospectively in a 
randomized trial. NT-proBNP was only available in about half 
of the patients and was unavailable in our validation cohort.
In conclusion, we found that a high-risk subset of one-third 
of HF patients without AF have a risk of stroke that is at least 
as great as in HF patients with AF. This high-risk subset can be 
identified by using simple clinical variables. This risk of stroke 
in these patients might be reduced by treatment with an oral anti-
coagulant. This hypothesis needs to be tested in a clinical trial.
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CLINICAL PERSPECTIVE
Some patients with heart failure but without atrial fibrillation may be at high risk of stroke and may potentially benefit from 
anticoagulation. We have combined and analyzed data from 2 large and contemporary heart failure trials, the Controlled 
Rosuvastatin in Multinational Trial Heart Failure (CORONA, ClinicalTrials.gov NCT00336336) and the Gruppo Italiano per 
lo Studio della Sopravvivenza nell’Insufficienza cardiac- Heart Failure trial (GISSI-HF, ClinicalTrials.gov NCT00206310), 
to provide a comprehensive description of the current incidence of and risk factors for stroke in patients with heart failure 
but without atrial fibrillation. We built a simple clinical predictive model which shows that about one-third of these patients 
have a risk of stroke similar to patients with atrial fibrillation. We validated this predictive model in another large data set. 
The risk of stroke in these patients might be reduced by treatment with an oral anticoagulant. A clinical trial using a novel 
oral anticoagulant agent in these high-risk patients not in atrial fibrillation would be of considerable interest. 
Go to http://cme.ahajournals.org to take the CME quiz for this article.
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SUPPLEMENTAL TABLES 
 
Supplementary Table 1. Baseline characteristics according to atrial fibrillation (AF) 
status at baseline. 
 
 
All patients 
(N= 9585) 
Without AF  
(n= 6054) 
AF  
(n= 3531) 
Demographics, n (%)    
Age (year) 70 ± 9 69 ± 10 73 ± 8  
<60 946 (10) 777 (13) 169 (5) 
60 - <65 1316 (14) 906 (15) 410 (12) 
65 - <75 3936 (41) 2539 (42) 1397 (40) 
≥75 3387 (35) 1832 (30) 1555 (44) 
Female sex 2212 (23) 1431 (24) 781 (22) 
NYHA class  
II 4717 (49) 3236 (53) 1481 (42) 
III 4680 (49) 2724 (45) 1956 (55) 
IV 188 (2) 94 (2) 94  (3) 
Duration of heart failure,  
   n (%) 
   
< 2 year 4122 (43) 2697 (45) 1425 (40) 
2-5 year 3218 (34) 2058 (34) 1160 (33) 
> 5 year 2241 (23) 1295 (24) 946 (27) 
LV Ejection Fraction, n (%) 32 ± 8  32 ± 7 33 ± 8 
>40% 461 (5) 216 (4) 245 (7) 
≤40%  4936 (52) 3138 (52) 1798 (51) 
≤30% 4188 (44) 2700 (45) 1488 (42) 
 
Baseline vital signs    
BMI, kg/m
2  27 ± 5  27 ± 4  27 ± 5  
BP, mmHg
    
Systolic 128 ± 17 128 ± 17 128 ± 17 
Diastolic 77 ± 9 77 ± 9 77 ± 9 
    Pulse pressure
 51 ± 13  52 ± 13 51 ± 13 
Heart rate, beats/min
 72 ± 12 71 ± 12 75 ± 14 
 
Laboratory measurements 
   
Total cholesterol, mmol/L 5.2 ± 1.1 5.3 ± 1.1 5.0 ± 1.1 
Serum creatinine, µmol/L    109 ± 30 107± 30 113 ± 30 
eGFR, ml/min/1.73m
2 63 ± 19 65 ± 20 60 ± 18 
eGFR <60, n(%) 4451 (46) 2581 (43) 1870 (53) 
NT-proBNP, pmol/L [median  
( IQR)] 
158 (21-295) 121 (9-233)  226 (63-289) 
 
Medical history, n (%) 
   
Myocardial infarction 4505 (47) 3003 (50) 1502 (43) 
Angina pectoris 4177 (44) 2521 (42) 1656 (47) 
CABG or PCI 2191 (23) 1472 (24) 719 (20) 
Hypertension 5659 (59) 3450 (57) 2209 (63) 
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All patients 
(N= 9585) 
Without AF  
(n= 6054) 
AF  
(n= 3531) 
Diabetes mellitus 2673 (28) 1714 (28) 959 (27) 
Stroke 832 (9) 424 (7) 408 (12) 
Pacemaker 1124 (12) 595 (10) 529 (15) 
ICD or CRT 437 (5) 297 (5) 140 (4) 
Peripheral artery disease 981 (10) 578 (10) 403 (11) 
Current smoker
 1172 (12) 864 (14) 308 (9) 
 
Medication, n (%) 
 
Diuretic (not aldosterone antagonist) 8534 (89) 5242 (87) 3292 (93) 
ACE inhibitor or ARB 8875 (93) 5646 (93) 3229 (92) 
Aldosterone antagonist 3800 (40) 2245 (37) 1555 (44) 
Beta-blocker 6619 (69) 4285 (71) 2334  (66) 
Digitalis glycoside 3478 (36) 1595 (26) 1883 (53) 
Long-acting nitrate  3128 (33) 2058 (34) 1070 (30) 
Anti-arrhythmic drug  1537 (16) 736 (12) 801 (23) 
Antiplatelet therapy 5352 (56) 4094 (68) 1258 (36) 
Anticoagulant therapy  3146 (33) 963 (16) 2183 (62) 
Antiplatelet or anti-coagulant therapy  8230 (86) 4953 (82) 3277 (93) 
Antidiabetic drugs   
insulin 688 (7) 467 (8) 221 (6) 
oral hypoglycaemic 1553 (16) 997 (17) 556 (16) 
 All continuous values are given in mean ± standard deviation unless stated otherwise. AF: atrial fibrillation;  n(%): number of 
observations (percentage of observations within the group); BMI: body mass index; CABG: coronary artery bypass graft; PCI: 
percutaneous coronary intervention; ICD: implantable cardioverter defibrillator;CRT: cardiac resyncronisation therapy; ACE: 
angiotensin converting enzyme; ARB: angiotensin receptor blocker. 
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Supplementary Table 2. Baseline characteristics according to AF status at baseline 
for patients with available NT-ProBNP measurement only.  
 
 
All patients 
(N= 4381) 
Without AF 
(n=2632) 
AF  
(n=1749) 
Demographics    
Age (year) 72± 8 71 ± 8 74 ± 7 
<60, n(%) 165 (4) 148 (6) 17 (1) 
60 - <65, n(%) 641 (15) 436 (17) 205 (12) 
65 - <75, n(%) 1867 (43) 1157 (44) 710 (41) 
≥75, n(%) 1708 (39) 891 (34) 817 (47) 
Female, n(%) 1048 (24) 665 (25) 383 (22) 
NYHA class, n (%)  
II 1849 (42) 1222 (46) 627 (36) 
III 2459 (56) 1370 (52) 1089 (62) 
IV 73 (2) 40 (2) 33 (2) 
Duration of heart failure (year),  
   n (%) 
   
< 2 1708 (39) 1064 (40) 644 (37) 
2-5 1563 (36) 956 (36) 607 (35) 
> 5 1110 (25) 612 (23) 498 (29) 
LV Ejection Fraction, %  31 ± 7 31 ± 7 32 ± 8 
>40, n(%) 97 (2) 50 (2) 47 (3) 
≤40 and >30, n(%) 2347 (54) 1401 (53) 946 (54) 
≤30, n(%) 1937 (44) 1181 (45) 756 (43) 
 
Baseline vital signs    
BMI, kg/m
2 27 ± 5 27 ± 5 27 ± 5 
BP, mmHg
    
Systolic 129 ± 17 129 ± 17 128± 17 
Diastolic 76 ± 9 76 ± 9 76 ± 9 
    Pulse pressure
 52 ± 13 53 ± 13 52 ± 13 
Heart rate, beats/min
 72 ± 12 70 ± 11 74 ± 13 
 
Laboratory measurements 
   
Total cholesterol, mmol/L 5.3 ± 1.1 5.4 ± 1.1 5.1 ± 1.1 
Serum creatinine, µmol/L    112 ± 29 111 ± 29 115 ± 28 
eGFR, ml/min/1.73m
2 60 ± 17 61 ± 17 58 ± 15 
eGFR <60, n(%) 2302 (53) 1295 (49) 1007 (58) 
NT-proBNP, pmol/L [median  
( IQR)] 
158 (21-295) 121(9-233)  226 (63-390) 
 
Medical history, n (%) 
   
Myocardial infarction 2350 (54) 1503 (574) 847 (484) 
Angina pectoris 2727 (62) 1610 (61) 1117 (64) 
CABG or PCI 1059 (24) 664 (25) 395 (23) 
Hypertension 2759 (63) 1622 (62) 1137 (65) 
Diabetes mellitus 1258 (29) 766 (29) 492 (28) 
Stroke 489 (11) 251 (10) 238 (14) 
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All patients 
(N= 4381) 
Without AF 
(n=2632) 
AF  
(n=1749) 
Pacemaker 497 (11) 244 (9) 253 (15) 
ICD or CRT 160 (4) 99 (4) 61 (4) 
Peripheral arterial disease 529 (12) 307 (12) 222 (13) 
Current smoker
 476 (11) 335 (13) 141 (8) 
 
Medication, n (%) 
 
Diuretic (not aldosterone antagonist) 3900 (89) 2273 (86) 1627 (93) 
ACE inhibitor or ARB 4065 (93) 2459 (93) 1606 (92) 
Aldosterone antagonist 1785 (41) 994 (38) 791 (45) 
Beta-blocker 3263 (75) 1981 (75) 1282 (73) 
Digitalis glycoside 1449 (33) 553 (21) 896 (51) 
Long-acting nitrate  1353 (31) 861 (33) 492 (28) 
Anti-arrhythmic drug  569 (13) 241 (9) 328 (19) 
Antiplatelet therapy 2578 (59) 1918 (73) 660 (38) 
Anticoagulant therapy  1497 (348) 431 (168) 1066 (618) 
Antiplatelet or anti-coagulant therapy  3895 (89) 2276 (87) 1619 (93) 
Antidiabetic drugs   
insulin 337 (8) 229 (9) 108 (6) 
oral hypoglycaemic 724 (17) 448 (17) 276 (16) 
 All values are given in mean ± standard deviation unless stated otherwise. AF:atrial fibrillation;  n(%): number of observations 
(percentage of observations within the group); BMI: body mass index; CABG: coronary artery bypass graft; PCI: percutaneous 
coronary intervention; ICD: implantable cardioverter defibrillator;CRT: cardiac resyncronisation therapy; ACE: angiotensin 
converting enzyme; ARB: angiotensin receptor blocker. 
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Supplementary Table 3. Baseline characteristics according to stroke outcome for 
patients without AF and available NT-ProBNP measurement only.  
 
 
All patients 
(N=2632) 
Non-Stroke 
(n=2538) 
Stroke  
(n=94) 
Demographics    
Age (year) 71 ± 8 71 ± 8 71 ± 8 
<60, n(%) 148 (6) 143 (6) 5 (5) 
60 - <65, n(%) 436 (17) 421 (17) 15 (16) 
65 - <75, n(%) 1157 (44) 1120 (44) 37 (39) 
≥75, n(%) 891 (34) 854 (34) 37 (40) 
Female, n(%) 665 (25) 648 (26) 17 (18) 
NYHA class, n (%)  
II 1222 (46) 1182 (47) 40 (23) 
III 1370 (52) 1319 (52) 51 (54) 
IV 40 (2) 37 (2) 3 (3) 
   Duration of heart failure (year),  
   n (%) 
   
< 2 1064 (40) 1022 (40) 42 (45) 
2-5 956 (36) 928 (37) 28 (30) 
> 5 612 (24) 588 (23) 24 (26) 
LV Ejection Fraction, %  31 ± 7 31 ± 7 31 ± 8 
>40, n(%) 50 (2) 48 (2) 2 (2) 
≤40 and >30, n(%) 1401 (53) 1357 (53) 44 (47) 
≤30, n(%) 1181 (45) 1133 (45) 48 (51) 
 
Baseline vital signs    
BMI, kg/m
2 27 ± 5 27 ± 5 27 ± 5 
BP, mmHg
    
Systolic 129 ± 17 129 ± 17 129 ± 17 
Diastolic 76 ± 9 76 ± 9 78 ± 9 
    Pulse pressure
 53 ± 13 53 ± 13 51 ± 13 
Heart rate, beats/min
 70 ± 11 70 ± 11 73 ± 12 
 
Laboratory measurements 
   
Total cholesterol, mmol/L 5.4 ± 1.1 5.4 ± 1.1 5.2 ± 0.9 
Serum creatinine, µmol/L    111 ± 29 111 ± 29 113 ± 29 
eGFR, ml/min/1.73m
2 61 ± 17 61 ± 17 61 ± 18 
eGFR <60, n(%) 1295 (49) 1245 (49) 50 (53) 
NT-proBNP, pmol/L [median (IQR)] 121 (9-233)  119 (8-230) 169 (41-297) 
 
Medical history, n (%) 
   
Myocardial infarction 1503 (57) 1448 (57) 55 (59) 
Angina pectoris 1610 (61) 1560 (610 50 (53) 
CABG or PCI 664 (25) 644 (25) 20 (21) 
Hypertension 1622 (62) 1566 (62) 56 (60) 
Diabetes mellitus 766 (29) 732 (29) 34 (36) 
Stroke 251 (10) 236 (9) 15 (16) 
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All patients 
(N=2632) 
Non-Stroke 
(n=2538) 
Stroke  
(n=94) 
Pacemaker 244 (9) 233 (9) 11 (12) 
ICD or CRT 99 (4) 95 (4) 4 (4) 
Peripheral arterial disease 307 (12) 295 (12) 12 (13) 
Current smoker
 335 (13) 322 (13) 13 (14) 
 
Medication, n (%) 
 
Diuretic (not aldosterone antagonist) 2273 (86) 2191 (86) 82 (87) 
ACE inhibitor or ARB 2459 (93) 2372 (93) 87 (93) 
Aldosterone antagonist 994 (38) 955 (38) 39 (41) 
Beta-blocker 1981 (75) 1913 (75) 68 (72) 
Digitalis glycoside 553 (21) 534 (21) 19 (20) 
Long-acting nitrate  861 (33) 823 (32) 38 (40) 
Anti-arrhythmic drug  241 (9) 232 (9) 9 (10) 
Antiplatelet therapy 1918 (73) 1848 (73) 70 (74) 
Anticoagulant therapy  431 (16) 414 (16) 17 (18) 
Antiplatelet or anticoagulant therapy  2276 (86) 2192 (86) 84 (89) 
Antidiabetic drugs   
insulin 229 (9) 215 (8) 14 (15) 
oral hypoglycaemic 448 (17) 437 (17) 11 (12) 
All values are given in mean ± standard deviation unless stated otherwise. AF:atrial fibrillation;  n(%): number of observations 
(percentage of observations within the group); BMI: body mass index; CABG: coronary artery bypass graft; PCI: percutaneous 
coronary intervention; ICD: implantable cardioverter defibrillator;CRT: cardiac resyncronisation therapy; ACE: angiotensin 
converting enzyme; ARB: angiotensin receptor blocker. 
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Supplementary Table 4. Exploratory unadjusted univariable analysis for outcome of 
stroke in patients without AF. 
 
Variables HR (95% CI) p-value 
Age (per 10 year increase) 1.48 (1.34-1.79) <0.001 
Female sex 0.84 (0.60-1.18) 0.313 
Heart rate (per 1bpm up to 70)* 1.03 (0.99-1.05) 0.056 
Systolic blood pressure (per 1mmHg increase) 1.00 (0.99-1.01) 0.962 
LVEF (per 5% increase up to 40%)
†
 0.87 (0.71-1.06) 0.172 
Creatinine (per 1 umol/L increase up to 350)
†
 1.01 (1.00-1.01) 0.001 
BMI (per 5kg/m
2
 increase up to 30)
†
 0.73 (0.59-0.90) 0.003 
NYHA class (III & IV vs. I & II) 1.83 (1.39-2.41) <0.001 
HF duration (> 5 years vs. ≤ 5 years) 1.22 (0.88-1.68) 0.228 
Current smoker 1.04 (0.71-1.53) 0.828 
Coronary heart disease (angina, MI, revascularisation, 
CABG, IHD) 
1.65 (1.21-2.24) 0.001 
Peripheral artery disease 1.73 (1.16-2.59) 0.007 
Previous Stroke 2.19 (1.45-3.30) <0.001 
Hypertension 1.16 (0.88-1.54) 0.287 
Insulin treated diabetes 1.74 (1.14-2.66) 0.011 
Cholesterol 0.90 (0.79-1.02) 0.107 
NT-proBNP (log)
‡
 1.29 (1.13-1.46) <0.001 
Significant level at conventional p<0.05 in bold. LVEF indicates left ventricular ejection fraction; BMI: body mass index; NYHA: 
New York Heart Association; MI: myocardial infarction; CABG: coronary arter bypas graft; IHD: ischaemic heart disease.  
* Heart rate was truncated to 70bpm to avoid co-linearity with possible atrial fibrillation. 
†
 The values were truncated to the level displayed due to individual variable’s non-linearity. 
‡  
Univariable analysis for log NT-ProBNP was performed for patients with NT-ProBNP measurements only. 
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Supplementary Table 5. Validation of “best clinical model” using CHARM HF-REF for patients without AF (n=3,349) 
Variables Hazard ratio Lower 95%CI Upper 95%CI Χ
2
-value P-value Coefficients 
derived 
from 
CORONA-
GISSI 
Age (per 10 year increase) 1.63 1.34 1.97 24.2 <0.001 0.331 
Previous Stroke 2.02 1.18 3.45 6.7 0.010 0.591 
Insulin treated diabetes 1.59 0.89 2.86 2.4 0.121 0.626 
BMI (per 5kg/m
2
 up to 30) 0.86 0.66 1.16 1.0 0.321 -0.301 
NYHA (III and IV) 1.04 0.70 1.56 <0.1 0.840 0.472 
See the appendix for explanation of how to use coefficients of the significant variables (in bold) to predict individual patient’s risk of stroke. AF indicates atrial fibrillation. AF defined as medical 
history of AF or baseline ECG that confirmed AF; BMI: body mass index; NYHA: New York Heart Association.  
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SUPPLEMENTAL FIGURES AND FIGURE LEGENDS 
 
Supplementary Figure 1. Cumulative incidence function of stroke for chronic heart 
failure patients with atrial fibrillation, according to anticoagulant treatment at baseline 
(with death as competing risk). AF indicates atrial fibrillation. 
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Supplementary Figure 2. Distribution of the risk score for stroke derived from model 
including NT-proBNP. 
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Supplementary Figure 3. Comparison of observed and expected strokes rates after 
3 years for patients categorised by tertiles of risk-scores derived from model 
including NT-proBNP.  
Observed, as read off from each Kaplan-Meier’s tertiles-group at 3 years; expected, 
as estimated from Cox model in each tertile.  
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Supplementary Figure 4. Validation using CHARM HF-REF, for patients without 
AF: Distribution of the risk score for stroke  – “best clinical model”, i.e. model without 
NT-proBNP. 
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Supplementary Figure 5. Cumulative incidence function plot for stroke by tertiles of 
their risk scores in patients without AF – “best clinical model” (using CHARM HF-
REF, for patients without AF- accounting death as competing risk). 
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Supplementary Figure 6.  Kaplan-Meier plot stroke for chronic heart failure patients 
according to atrial fibrillation status at baseline.  
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Supplementary Figure 7.  Kaplan-Meier plot for stroke by tertiles of their risk scores 
in patients without AF – model including NT-proBNP. AF indicates atrial fibrillation. 
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Supplementary Figure 8. Kaplan-Meier plot for stroke by tertiles of their risk scores 
in patients without AF – “best clinical model” (using CHARM HF-REF, for patients 
without AF). 
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Appendices   
 Appendix 1. Examples of risk score calculation using the models presented in 
Tables 2 and 3 
 
This example illustrates the use of Tables 2 and 3, and associated Figure 3 and 
Supplementary Figure II, respectively, to calculate the risk score of stroke in individual 
patients. 
For example, consider a patient aged 70 years in NYHA functional class II with a BMI of 25 
kg/m2 and a previous stroke. Using the coefficients in Table 2, each multiplied by 10, this 
patient’s risk score for stroke is: (7 x 3.11) + [5 x (-3.01)] +  5.91 = 12.63. Note that age in 
decades, hence 70 becomes 7; BMI in steps of 5, hence BMI of 25 becomes 5.  
For patient with available NT pro-BNP measurement, risk score for stroke can be estimated 
using coefficients in Table 3 and Supplementary Figure II, using similar steps as described 
above.  
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Appendix 2. List of the Investigators of the Controlled Rosuvastatin 
Multinational Study in Heart Failure (CORONA) and GISSI-Heart 
Failure (GISSI-HF) 
 
CORONA group: John Kjekshus, Eduard Apetrei, Vivencio Barrios, Michael Böhm, John 
G.F. Cleland, Jan H. Cornel, Peter Dunselman, Cândida Fonseca, Assen 
Goudev, Peer Grande, Lars Gullestad, Åke Hjalmarson, Jaromir Hradec, 
András Jánosi, Gabriel Kamenský, Michel Komajda, Jerzy Korewicki, Timo 
Kuusi, François Mach, Vyacheslav Mareev, John J.V. McMurray, Naresh 
Ranjith, Maria Schaufelberger, Johan Vanhaecke, Dirk J. van Veldhuisen, 
Finn Waagstein, Hans Wedel, John Wikstrand. 
 
GISSI-HF group: Luigi Tavazzi, Gianni Tognoni, Aldo P Maggioni, Roberto Marchioli, 
Roberto Latini, Maria Grazia Franzosi, Gian Luigi Nicolosi, Maurizio Porcu, 
Simona Barlera, Donata Lucci.  
